Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis

Blood

Volumn 127, Issue 10, 2016, Pages 1317-1324

  Marty, Caroline ^a,b   Pecquet, Christian ^c,d   Nivarthi, Harini ^e   El Khoury, Mira ^a,b   Chachoua, Ilyas ^c,d   Tulliez, Micheline ^a,b   Villeval, Jean Luc ^a,b   Raslova, Hana ^a,b   Kralovics, Robert ^e   Constantinescu, Stefan N ^c,d   Plo, Isabelle ^a,b   Vainchenker, William ^a,b  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; JAK2 PROTEIN, MOUSE; MPL PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEMATOPOIESIS; MEGAKARYOCYTE; MOUSE; MOUSE MODEL; MYELOFIBROSIS; NONHUMAN; OSTEOSCLEROSIS; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; ANIMAL; COMPLICATION; FRAMESHIFT MUTATION; GENETICS; INDEL MUTATION; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; PRIMARY MYELOFIBROSIS;

ANIMALS; CALRETICULIN; FRAMESHIFT MUTATION; INDEL MUTATION; JANUS KINASE 2; MEGAKARYOCYTES; MICE; MICE, MUTANT STRAINS; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOSIS;

EID: 84960864909     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-679571     Document Type: Article

References (22)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114(5):937-951.
2. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714-3719.
3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
4. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calciumbuffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417(3):651-666.
5. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269(5220):79-81.
6. Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution. Leukemia. 2015;29(1):249-252.
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
8. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90(11):4369-4383.
9. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
10. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
11. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11): 4274-4281.
12. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538.
13. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
14. Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood. 2013;122(8): 1464-1477.
15. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol. 2014;89(8):E121-E124.
16. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms [published online ahead of print October 9, 2015]. Leukemia. doi:10.1038/leu.2015.277.
17. Kent DG, Li J, Tanna H, et al. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion [published correction appears in PLoS Biol. 2015;13(3):e1002092]. PLoS Biol. 2013;11(6):e1001576.
18. Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127(10):1325-1335.
19. Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617Finduced myeloproliferative neoplasm. Blood. 2014;124(26):3956-3963.
20. Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014;370(12):1168-1169.
21. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006; 441(7092):475-482.
22. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per La Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.